Hepatitis C Virus Genotypes 1 and 2 Respond to Interferon-a with Different
V. KineticsMichinori KoharaTsukasa TanakaKyoko Tsukiyama‐KoharaSatoshi TanakaM. MizokamiJohnson Y. N. LauNobutaka Hattori
71
Citation
0
Reference
10
Related Paper
Citation Trend
Abstract:
Responses of patients infected with chronic hepatitis C virus (HCV) to interferon-alpha (IFN-alpha) treatment were studied. HCV genotypes were determined by molecular and serologic techniques. Levels of HCV viremia were determined by quantitative reverse transcription-polymerase chain reaction. Infection with HCV genotype 2 or low pretreatment HCV viremia levels in subjects infected with genotype 1 were associated with favorable (complete and sustained) responses (CR-SR; P < .001) to IFN-alpha treatment. HCV viremia levels in genotype 2 infection were significantly lower (P < .05) than in genotype 1 infection. The reduction rates of serum HCV RNA levels were four times higher in patients with genotype 2 infection than in those infected with genotype 1. The proportion of patients with CR-SR who experienced virologic relapse after completion of IFN-alpha treatment was higher for those infected with genotype 1. The proportion of patients with CR-SR and genotype 1 infection increased linearly in accordance with increases in single or total IFN-alpha dose.Keywords:
Hepatitis C
Topics:
To determine the prevalence of HCV genotypes in Slovenia, 203 subjects infected with hepatitis C virus (HCV) were studied using the Inno-Lipa HCV II assay (Innogenetics, Belgium). Of 21 patients infected by blood transfusion 19% had HCV subtype 1a, 81% had subtype 1b, and none of them was infected with genotype 3. In chronic hepatitis C patients infected by unknown cause subtype 1b was the most prevalent (54.4%), followed by subtype 1a (24.6%), genotype 3 (15.8%) and genotype 2 (5.2%). Genotype 3 (45.9%) and subtype 1a (43.2%) predominated among 74 intravenous drug users. In 37 haemodialysis patients genotypes 1 and 2 were almost equally frequent (40.5% and 37.8%, respectively), followed by genotype 3 (21.6%). Significant differences in HCV genotype distribution among distinct epidemiological groups observed in Slovenia indicate a close relationship between certain HCV genotypes and particular routes of viral transmission.
Hepatitis C
Cite
Citations (18)
Objective To analyze the distribution of hepatitis C virus(HCV)genotype in Changchun Region,China and its relationship to HCV RNA content as well as infectious route and degree of liver disease.Methods The serum specimens from 82 anti-HCV patients were determined for HCV RNA by fluorescent quantitative PCR,and analyzed for HCV genotype by PCR using type-specific primers,based on which the relationship of genotype to infectious route,HCV RNA content and degree of liver disease was analyzed.Results Of the 78 HCV RNA-positive serum specimens,4(5.1%)were identified as genotype 1a,38(48.7%)as 1b,26(33.3%)as 2a,9(11.6%)as 2b,and 1(1.3%)as 3a.No mixed infection of HCV of various genotypes was observed.No sig-nificant difference was observed in the distributions of HCV genotypes in the patients with blood-transmitted and non-blood-transmitted hepatitis C.The RNA content of HCV of genotype 1b was significantly higher than that of genotype 2a.However,the distribution of genotypes showed significant difference in the patients with liver diseases at various degrees caused by HCV infection.The propor-tions of genotype 1b in patients with chronic hepatitis C,liver cirthosis and liver cancer were significantly higher than those of other genotypes.Conclusion The epidemic HCV strains in Changchun Region were of genotypes 1b and 2a.No significant relationship was observed between HCV genotype and infectious route.The HCV content of genotype 1b was significantly higher than that of genotype 2a.HCV genotype showed a certain relationship to the severity of chronic hepatitis C and the onsets of liver cirthosis and liver cancer.
Hepatitis C
Liver disease
Cite
Citations (1)
The genotypic distribution of hepatitis C virus (HCV) isolated from blood donors from four major regions of Thailand was studied by reverse hybridization assays. PCR-amplified products from the 5' noncoding and core regions of the viral genome were hybridized to genotype- and subtype-specific probes which were immobilized on the nitrocellulose membrane. Of 332 anti-HCV-positive plasma samples studied, 71% contained HCV RNA. HCV genotype 3a was the most prevalent genotype (39%), followed by genotype 1b (20%) and genotype 6 group variants (18%). HCV genotype 1a was identified among 9% of all isolates. Other genotypes (genotype 1 which was neither 1a nor 1b, genotype 3b, and an unclassified genotype) were uncommon. There was no difference in the mean age of the donors infected with different HCV genotypes. The genotypic distribution pattern of HCV was similar among HCV isolates from different regions of Thailand.
Hepatitis C
Cite
Citations (45)
Since hepatitis C virus (HCV) was first identified in 1989, the impact of HCV infection on the HIV-infected population has been steadily increasing. It is now known that HCV affects the course and treatment of HIV disease in coinfected individuals (those infected with both HCV and HIV). Although there are significant data regarding the treatment of HCV in non-coinfected individuals, there are numerous questions that still remain regarding how to monitor and treat HCV infection in the coinfected population. This article reviews the available data regarding treatment of HCV in the coinfected population as well as how these individuals should be monitored, before and during HCV therapy, as well as how to address the numerous side effects associated with HCV treatment. To meet the demands of the coinfected population, HIV nurses must be willing to expand their knowledge to support, educate, assess, and advocate for coinfected individuals.
Hepatitis C
Cite
Citations (4)
Hepatitis C
Viral Hepatitis
Antiviral drug
Antiviral Therapy
Combination therapy
Cite
Citations (163)
Hepatitis C viruses (HCV) present in 110 Italian patients were characterized by genotype-specific PCRs. Among the 65 cases of community-acquired hepatitis, HCV genotype II was dominant (60%), followed by genotypes IV (15%), III (11%), and I (3%). Among the 45 hemophilia-associated cases, the distribution of the four HCV genotypes was markedly different: genotype I was the most prevalent (61%), followed by genotypes II (25%), III (4%), and IV (2%). Double infections were observed in eight patients. Two HCV remained unclassified. For the 45 community-acquired cases from which a liver biopsy was available, genotype II was associated with more severe liver damage than the other types.
Hepatitis C
Cite
Citations (90)
CD81
Hepatitis C
NS2-3 protease
Cite
Citations (17)
The hepatitis C virus (HCV) genotype affects clinical outcomes of HCV infection, in terms of the response to antiviral therapy and progression of chronic liver diseases, and shows geographic differences in distribution. The aim of this study was to elucidate the HCV genotypes in patients with chronic HCV infection in Jeju, which is an island off the Korean peninsula.The study population consisted of 162 patients with anti-HCV antibodies and HCV-RNA. HCV genotypes were determined using genotype specific primers.HCV genotype 2a predominated (62.3%), followed by genotype 1b (34.0%) and 2b (3.7%). The prevalence of genotypes differed significantly with age, with HCV genotypes 1 and 2 being more frequent in older and younger subjects (P=0.035), respectively. HCV-RNA levels were higher in patients with genotype 1 than in those with genotype 2 (P=0.001). HCV genotype was not significantly related to sex, clinical diagnosis and potential risk factors.HCV genotype 2a is most common in Jeju, followed by genotype 1b. Our results suggest that the distribution of the HCV genotype differs between regions in Korea.
Hepatitis C
Cite
Citations (10)
From 1996 to 2002, hepatitis C virus (HCV) typing was prospectively performed for 1,281 unselected HCV-infected and viremic patients, irrespective of their clinical status. Eighty-three patients (6.5%) were coinfected with human immunodeficiency virus (HIV) and HCV. A total of 1,195 strains were identified by a serotype screening (Murex HCV Serotyping 1-6 assay) and/or genotyping (Inno-LiPA HCV II) test. The distribution of HCV types showed an unusually high rate of type 5 (14.2%) that was stable over time and was the third most frequent type, after type 1 (59.1%) and type 3 (15.1%). HCV type 5 was more frequent in patients who were older than 50 (P = 10(-6)), but its frequency did not differ significantly by gender (P = 0.21). Serotyping was performed for 1,160 strains but failed for 30.2% of them. The efficiency depended on HIV status (for HCV-HIV-coinfected patients, half of the strains were untypeable) and HCV type. Genotyping was performed for 428 samples, with an overall efficiency of 99.3%. It failed in three cases, which were subsequently identified as HCV type 2. Serotyping and genotyping results for 39 patients showed discrepancies between the two methods for 4 patients, who had HCV type 2, type 6, or mixed infections. Thus, HCV type 5 may also be encountered frequently in Western countries. Its apparent confinement to a restricted area raises the question of how it emerged and underscores the need for further studies of HCV type prevalence, routes of transmission, pathogenicity, and responses to treatment.
Hepatitis C
Cite
Citations (56)
The majority of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection occurs among persons who inject drugs. Rapid improvements in responses to HCV therapy have been observed, but liver-related morbidity rates remain high, given notoriously low uptake of HCV treatment. Advances in HCV therapy will have a limited impact on the burden of HCV-related disease at the population-level unless barriers to HCV education, screening, evaluation, and treatment are addressed and treatment uptake increases. This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
Hepatitis C
Liver disease
Cite
Citations (177)